or they leave it to a BP whose representatives have a number of products to sell in their portfolio. I recall Sarissa saying this would be a more efficient way of selling Vascepa!!!!!!!
Why have a branded generic if you are launching a once a day pill ( MND-2019 ? ) Once a day is obviously preferred ...better patient compliance ...but insurers like Kaiser won't cover unless its priced the same or lower then the generic 4 caps a day This is why Kaiser won't cover Inclisiran ...which is 2 sub Q shots a year ( after the first year ) and would have far better patient compliance ......but is more expensive then Repatha which is a sub Q every 2 wks.
So to be covered by a Co like Kaiser ....MND-2019 would have to price ( monthly cost ) the same or better than generic V . Your other question ...How will Holt grow the US market ? He won't . The US is lost to Dr Reddy and the other generics Question is ...Can he grow the UK and EU market ...and why did Italy refuse reimbursement ?
News 
Market Data 
Discover 
